Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: The lipid nanoparticle compositions provided herein preferentially deliver and/or transfect the lung. Also provided herein are therapeutic polynucleotides, e.g. TERT mRNA, which may be delivered with the LNP formulations for the treatment of lung disease and fibrosis.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: In a pump, a flexible tube passes through the pump and is held “normally closed” at an output constriction. The pump includes a pump body and a pump member that can perform two functions by their relative motion. The first function is to open and close an input constriction of the flexible tube. The second function is to compress the section of flexible tube between the input constriction and the output constriction. This section of tube acts as the pump chamber. When closed, the input constriction provides a greater impediment to fluid flow than the output constriction. Therefore, when the input constriction is closed and the pump chamber is compressed, fluid flows out of the pump past the output constriction. When the input constriction is open and compression of the pump chamber is removed, the output constriction closes and fluid can enter the pump by flowing past the location of the input constriction.

Abstract: Methods are provided for the ex vivo manipulation of cells, stem cells and other reproductive cells, by manipulating the cells in a container or device comprising an elastic substrate, wherein the substrate has an elasticity that mimics the elasticity of a native microenvironment of the cell.

Abstract: One or more cells can be cultured when confined in space by barriers. The distance between barriers can be comparable to the size of a cell to be cultured. The space between barriers can also be sufficiently small to allow control of cell properties or monitoring of the cell(s) cultured therein. The cell(s) may be confined completely or may be mobile between two opposing barrier surfaces. The gap between two opposing barriers may be sufficiently narrow to allow only a monolayer of cells to be cultured. A barrier can be transparent. The surfaces of the barriers may have one or more pre-selected characteristics that mimic the characteristics of a biological niche of the cells(s). The number of cells in a cell culture may be limited to permit control of properties of individual cells. The cultured cell(s) may be monitored, such as imaged, over a long period of time, using standard bright field or fluorescent imaging techniques.

Abstract: Provided is a sequenced fluid control device that includes a pneumatic driver module, a fluid cartridge having at least one fluid chamber and at least one waste chamber, and at least one sample delivery element disposed to sealably contact the fluid cartridge forming a main chamber containing a sample, where the fluid cartridge is also disposed to sealably contact the pneumatic driver module. The pneumatic driver module injects gas into or withdraws gas from the fluid cartridge, where the gas directly contacts at least one fluid causing at least one fluid to flow through channels disposed to connect at least one fluid chamber to the sample delivery element and disposed to connect the sample delivery element to the at least one waste chamber or waste channel, where a sample on the sample delivery element is exposed to the at least one fluid.

Abstract: In a pump, a flexible tube passes through the pump and is held “normally closed” at an output constriction. The pump includes a pump body and a pump member that can perform two functions by their relative motion. The first function is to open and close an input constriction of the flexible tube. The second function is to compress the section of flexible tube between the input constriction and the output constriction. This section of tube acts as the pump chamber. When closed, the input constriction provides a greater impediment to fluid flow than the output constriction. Therefore, when the input constriction is closed and the pump chamber is compressed, fluid flows out of the pump past the output constriction. When the input constriction is open and compression of the pump chamber is removed, the output constriction closes and fluid can enter the pump by flowing past the location of the input constriction.

Abstract: One or more cells can be cultured when confined in space by barriers. The distance between barriers can be comparable to the size of a cell to be cultured. The space between barriers can also be sufficiently small to allow control of cell properties or monitoring of the cell(s) cultured therein. The cell(s) may be confined completely or may be mobile between two opposing barrier surfaces. The gap between two opposing barriers may be sufficiently narrow to allow only a monolayer of cells to be cultured. A barrier can be transparent. The surfaces of the barriers may have one or more pre-selected characteristics that mimic the characteristics of a biological niche of the cells(s). The number of cells in a cell culture may be limited to permit control of properties of individual cells. The cultured cell(s) may be monitored, such as imaged, over a long period of time, using standard bright field or fluorescent imaging techniques.